FDA Approves Osimertinib for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy
On September 25, 2024, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso®) for adult patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R variants, as detected by an FDA-approved test.